In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.
The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.
As consumer genomics firms ramp up marketing for Alzheimer's risk tests, one support group says experts should help people understand the results and potential negative effects.
Distinct alterations of the APP gene in Alzheimer's patients appear to depend on reverse transcriptase, suggesting HIV antiretroviral drugs as a potential new treatment.
GWAS summary statistics data led to three main loci with ties to both Alzheimer's and cardiovascular disease, with additional enrichment at lipid-related sites.
The thousands of differentially acetylated peaks were enriched in regions harboring genes with disease-related pathology.
According to the researchers, led by a team at the University of Cambridge, detecting somatic brain mutations in patients during their life may increase diagnostic precision and lead to new therapies.
An analysis of post-mortem brain transcripts led to Alzheimer's-related alternative gene splicing and expression events, including those influenced by known risk alleles.
IQuity develops tests that use RNA expression data to predict, detect, and monitor disease, as well as stratify patients by severity of disease.
Cytox will work with AIBL to test new algorithms for identifying individuals most at risk for developing Alzheimer's disease using its current technologies.
The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.